Search Results

MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO).

MicroTransponder®, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners, a multi-stage investment firm.

MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services awarded the Vivistim® Paired VNS™ System transitional pass-through status, expanding access to Medicare beneficiaries who are ischemic stroke survivors interested in using the breakthrough technology to help improve their hand and arm mobility.

MicroTransponder, Inc. today announced United States Food and Drug Administration (FDA) Premarket Approval of the Vivistim Paired VNS™ System, which significantly improves the effectiveness of rehabilitation therapy for stroke survivors with moderate to severe upper extremity impairment six months after stroke.

MicroTransponder®, Inc. reached a milestone Tuesday with the first commercial use of its Vivistim® Paired VNS™ System.

MicroTransponder® Inc. announced that its Vivistim® Paired VNS™ System won the Neurotech Reports Gold Electrode Award for best new product.

The Vivistim clinical trial team won the 2022 Paul Dudley White International Scholar Award for submitting the highest-ranked abstract from the United Kingdom to the American Heart Association’s International Stroke Conference 2022, according to MicroTransponder®, Inc.

The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System)

MicroTransponder Inc., today announced that the pivotal clinical trial results for the Company’s investigational Vivistim® Paired Vagus Nerve Stimulation (VNS) System have been published in The Lancet.